PMID-22724573 – Melanotan-Associated Melanoma in Situ
Ong S, Bowling J. "Melanotan-associated melanoma in situ," Australasian Journal of Dermatology, 2012;53(4):301-302.
Quick Reference
| Property | Value |
|---|---|
| PMID | 22724573 |
| DOI | — |
| Year | 2012 |
| Journal | Australasian Journal of Dermatology |
| Study Type | Case Report |
| Evidence Level | IV |
| Sample | n=1 |
| Peptide(s) Studied | Melanotan 1, Melanotan II |
Key Findings
- Melanoma in situ diagnosed in a patient who had been using melanotan products for self-tanning purposes
- The melanoma was detected during monitoring of changing nevi noted after melanotan use
- Multiple nevi showed dermoscopic changes during melanotan use (increased pigmentation, structural changes)
- This represents one of the earliest published case reports linking melanotan to melanoma
- The in situ stage suggests early detection was possible due to the increased surveillance triggered by nevus changes
Study Design
Case report documenting a single case of melanoma in situ in a melanotan user. Includes clinical description and dermoscopic findings of multiple changing nevi.
Limitations
- Single case report; no causal inference possible
- Patient's UV exposure history and baseline risk factors incompletely described
- Specific melanotan product (MT-I vs. MT-II) and dosing not well characterized
- Unregulated product source — purity and actual peptide content unknown
- No denominator data for melanotan users to estimate relative risk
Clinical Relevance
An early case report contributing to the accumulating literature on melanotropic peptide safety. The observation that multiple nevi changed during melanotan use is clinically important — practitioners should advise patients on regular self-examination and professional skin checks. The melanoma in situ diagnosis demonstrates that early detection is possible with appropriate surveillance. Supports the recommendation for baseline mole mapping before initiating any melanotropic peptide protocol.
Related
#research #case-report #evidence-level-IV #cancer